View Financial HealthJune Industries 배당 및 자사주 매입배당 기준 점검 0/6June Industries 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesReported Earnings • May 22Full year 2026 earnings released: ₹0.097 loss per share (vs ₹0 in FY 2025)Full year 2026 results: ₹0.097 loss per share (further deteriorated from ₹0 in FY 2025). Revenue: ₹2.16m (up 12% from FY 2025). Net loss: ₹4.61m (loss widened ₹4.60m from FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 174 percentage points per year, which is a significant difference in performance.공시 • Apr 24June Industries Limited to Report Q4, 2026 Results on May 15, 2026June Industries Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 15, 2026Reported Earnings • Feb 11Third quarter 2026 earnings released: ₹0.02 loss per share (vs ₹0 in 3Q 2025)Third quarter 2026 results: ₹0.02 loss per share (further deteriorated from ₹0 in 3Q 2025). Net loss: ₹942.0k (loss widened ₹920.0k from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 143% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth.공시 • Jan 21June Industries Limited to Report Q3, 2026 Results on Feb 10, 2026June Industries Limited announced that they will report Q3, 2026 results on Feb 10, 2026New Risk • Dec 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (₹780k revenue, or US$8.6k). Market cap is less than US$10m (₹400.9m market cap, or US$4.44m). Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change).Buy Or Sell Opportunity • Nov 20Now 23% undervaluedOver the last 90 days, the stock has risen 4.8% to ₹10.19. The fair value is estimated to be ₹13.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 13% over the last 3 years. Earnings per share has grown by 133%.Reported Earnings • Nov 18First half 2026 earnings released: ₹0.018 loss per share (vs ₹0.002 profit in 1H 2025)First half 2026 results: ₹0.018 loss per share (down from ₹0.002 profit in 1H 2025). Net loss: ₹869.0k (down ₹947.0k from profit in 1H 2025). Over the last 3 years on average, earnings per share has increased by 133% per year but the company’s share price has only increased by 70% per year, which means it is significantly lagging earnings growth.공시 • Nov 03Kashyap Tele-Medicines Limited to Report First Half, 2026 Results on Nov 12, 2025Kashyap Tele-Medicines Limited announced that they will report first half, 2026 results on Nov 12, 2025공시 • Sep 26+ 1 more updateKashyap Tele-Medicines Limited Appoints Kalpesh Bipin Sheth as Managing Director, Effective May 23, 2025Kashyap Tele-Medicines Limited at its AGM held on September 24, 2025 announced the appointment of Mr. Kalpesh Bipin Sheth (DIN: 00405151) as Managing Director of the Company, effective 23rd May, 2025 for the period of five consecutive years.공시 • Aug 25Kashyap Tele-Medicines Limited, Annual General Meeting, Sep 24, 2025Kashyap Tele-Medicines Limited, Annual General Meeting, Sep 24, 2025, at 11:30 Indian Standard Time.Reported Earnings • Aug 15First quarter 2026 earnings released: ₹0.006 loss per share (vs ₹0.001 profit in 1Q 2025)First quarter 2026 results: ₹0.006 loss per share (down from ₹0.001 profit in 1Q 2025). Net loss: ₹298.0k (down ₹332.0k from profit in 1Q 2025).공시 • Aug 09Kashyap Tele-Medicines Limited to Report Q1, 2026 Results on Aug 14, 2025Kashyap Tele-Medicines Limited announced that they will report Q1, 2026 results on Aug 14, 2025Board Change • Aug 01High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Non-Executive & Independent Director Hiren Mehta was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.New Risk • May 24New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₹860k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹860k free cash flow). Revenue is less than US$1m (₹1.9m revenue, or US$23k). Market cap is less than US$10m (₹432.8m market cap, or US$5.08m).공시 • May 15Kashyap Tele-Medicines Limited to Report Q4, 2025 Results on May 23, 2025Kashyap Tele-Medicines Limited announced that they will report Q4, 2025 results on May 23, 2025공시 • Apr 07Kashyap Tele-Medicines Limited Announces Resignation of Ms. Jyoti Sahu as Whole Time Company Secretary, Compliance Officer, Effective April 6, 2025Kashyap Tele-Medicines Limited announced resignation of Ms. Jyoti Sahu (ICSI A72072) from the position of Whole Time Company Secretary, Compliance Officer and Key Managerial Personnel and she shall not be associated with the Company with effect from 6th April, 2025 to explore further professional growth opportunities. Further there are no other material reasons for resignation other than the one mentioned in her resignation letter dated 5th April, 2025.Reported Earnings • Feb 13Third quarter 2025 earnings releasedThird quarter 2025 results: EPS: ₹0. Revenue: ₹390.0k (down 14% from 3Q 2024). Net loss: ₹22.0k (down 375% from profit in 3Q 2024).공시 • Feb 05Kashyap Tele-Medicines Limited to Report Q3, 2025 Results on Feb 12, 2025Kashyap Tele-Medicines Limited announced that they will report Q3, 2025 results on Feb 12, 2025Reported Earnings • Nov 14Second quarter 2025 earnings releasedSecond quarter 2025 results: EPS: ₹0.001. Revenue: ₹550.0k (down 9.8% from 2Q 2024). Net income: ₹44.0k (up ₹42.0k from 2Q 2024). Profit margin: 8.0% (up from 0.3% in 2Q 2024). The increase in margin was driven by lower expenses.New Risk • Nov 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.4% average weekly change). Earnings have declined by 29% per year over the past 5 years. Revenue is less than US$1m (₹2.0m revenue, or US$24k). Market cap is less than US$10m (₹110.2m market cap, or US$1.31m).공시 • Nov 06Kashyap Tele-Medicines Limited to Report Q2, 2025 Results on Nov 11, 2024Kashyap Tele-Medicines Limited announced that they will report Q2, 2025 results on Nov 11, 2024공시 • Aug 28Kashyap Tele-Medicines Limited Announces Cessation of Surabhi Agrawal from the Post of Non-Executive Independent DirectorKashyap Tele-Medicines Limited announced that the Board of Directors in its meeting held on 28 August, 2024, has inter-alia considered and taken note of the cessation of Mrs. Surabhi Agrawal from the post of Non-Executive Independent Director of the Company effective from 22 August, 2024 upon completion of second term of five consecutive years on 21 August, 2024.공시 • Jul 30Kashyap Tele-Medicines Limited to Report Q1, 2025 Results on Aug 05, 2024Kashyap Tele-Medicines Limited announced that they will report Q1, 2025 results on Aug 05, 2024Reported Earnings • Jul 26Full year 2024 earnings released: ₹0.006 loss per share (vs ₹0.001 profit in FY 2023)Full year 2024 results: ₹0.006 loss per share (down from ₹0.001 profit in FY 2023). Revenue: ₹1.92m (down 2.3% from FY 2023). Net loss: ₹300.0k (down ₹331.0k from profit in FY 2023).공시 • Jul 22Kashyap Tele-Medicines Limited, Annual General Meeting, Aug 12, 2024Kashyap Tele-Medicines Limited, Annual General Meeting, Aug 12, 2024, at 15:00 Indian Standard Time.공시 • Jul 18Kashyap Tele-Medicines Limited Announces Change in Category of Directorship of Amrita Khetan from Non-Executive Non-Independent Director to Non-Executive Independent DirectorKashyap Tele-Medicines Limited at its board meeting held on July 18, 2024 approved change in category of directorship of Mrs. Amrita Khetan (DIN: 02781781) from existing category of "Non-Executive Non-Independent Director" to "Non-Executive Independent Director" of the Company for the first term of 5 consecutive years w.e.f. 19th July, 2024 to 18th July, 2029. Mrs. Amrita Khetan has completed Master of Arts in Sociology from Techno Global University and Bachelor of Arts from Kanpur Vishwavidyalaya. She has approx. 12 years of rich experience in mentorship in Programme Management. She is working as a Team Lead & Pedagogical mentor in Redbricks Education Foundation and also experienced and expertised in strategic thinking and Business management.New Risk • May 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 49% per year over the past 5 years. Revenue is less than US$1m (₹1.9m revenue, or US$23k). Market cap is less than US$10m (₹112.1m market cap, or US$1.34m). Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change).공시 • May 12Kashyap Tele-Medicines Limited to Report Q4, 2024 Results on May 17, 2024Kashyap Tele-Medicines Limited announced that they will report Q4, 2024 results on May 17, 2024공시 • Feb 28Kashyap Tele-Medicines Limited Appoints Jyoti Sahu as Company Secretary and Compliance OfficerKashyap Tele-Medicines Limited at its board meeting held on February 27, 2024, has appointed Ms. Jyoti Sahu (ACS-72072), Member of the Institute of Companies Secretaries of India as Company Secretary and Compliance Officer of the Company with effect from February 27, 2024.New Risk • Feb 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.7% average weekly change). Earnings have declined by 49% per year over the past 5 years. Revenue is less than US$1m (₹1.9m revenue, or US$23k). Market cap is less than US$10m (₹119.3m market cap, or US$1.44m).Reported Earnings • Feb 11Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: ₹455.0k (down 16% from 3Q 2023). Net income: ₹8.0k (up 33% from 3Q 2023). Profit margin: 1.8% (up from 1.1% in 3Q 2023). The increase in margin was driven by lower expenses.공시 • Feb 01Kashyap Tele-Medicines Limited to Report Q3, 2024 Results on Feb 09, 2024Kashyap Tele-Medicines Limited announced that they will report Q3, 2024 results on Feb 09, 2024공시 • Dec 28Kashyap Tele-Medicines Limited Announces Resignation of Mr. Paritosh Trivedi as Company Secretary and Compliance OfficerKashyap Tele-Medicines Limited informed that the Board of Directors at their meeting held on 27 December, 2023, considered and approved, resignation of Mr. Paritosh Trivedi, Company Secretary & Compliance Officer of the Company. Accordingly, he shall be relieved from his current responsibilities with effect from closing hours of 27th December, 2023. Reason for change: Resignation due to some personal an unavoidable reasons.공시 • Oct 26Kashyap Tele-Medicines Limited to Report Q2, 2024 Results on Nov 06, 2023Kashyap Tele-Medicines Limited announced that they will report Q2, 2024 results on Nov 06, 2023New Risk • Aug 04New major risk - Revenue and earnings growthEarnings have declined by 70% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 70% per year over the past 5 years. Revenue is less than US$1m (₹1.9m revenue, or US$23k). Market cap is less than US$10m (₹92.6m market cap, or US$1.12m). Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change).공시 • Jul 30Kashyap Tele-Medicines Limited to Report Q1, 2024 Results on Aug 03, 2023Kashyap Tele-Medicines Limited announced that they will report Q1, 2024 results on Aug 03, 2023Reported Earnings • Jul 15Full year 2023 earnings released: EPS: ₹0.001 (vs ₹0.36 loss in FY 2022)Full year 2023 results: EPS: ₹0.001 (up from ₹0.36 loss in FY 2022). Revenue: ₹1.97m (flat on FY 2022). Net income: ₹31.0k (up ₹17.3m from FY 2022). Profit margin: 1.6% (up from net loss in FY 2022).공시 • Jul 13Kashyap Tele-Medicines Limited, Annual General Meeting, Aug 03, 2023Kashyap Tele-Medicines Limited, Annual General Meeting, Aug 03, 2023, at 12:00 Indian Standard Time. Agenda: To consider and adopt the Audited Financial Statements of the Company for the Financial Year ended March 31, 2023 together with the Report of the Board of Directors and Report of the Statutory Auditors thereon; to appoint a Director in place of Ms. Amrita Khetan who retires by rotation and being eligible, offers herself for re-appointment; to consider and approve appointment of M/s. Ravi Karia & Associates, Chartered Accountants, Ahmedabad, as Statutory Auditors of the Company and to fix their remuneration; and to consider other matters if any.New Risk • Jun 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.0% average weekly change). Revenue is less than US$1m (₹2.0m revenue, or US$24k). Market cap is less than US$10m (₹94.5m market cap, or US$1.15m).Reported Earnings • Jun 03Full year 2023 earnings released: EPS: ₹0.001 (vs ₹0.36 loss in FY 2022)Full year 2023 results: EPS: ₹0.001 (up from ₹0.36 loss in FY 2022). Revenue: ₹1.97m (flat on FY 2022). Net income: ₹31.0k (up ₹17.3m from FY 2022). Profit margin: 1.6% (up from net loss in FY 2022).공시 • May 23Kashyap Tele-Medicines Limited to Report Q4, 2023 Results on May 29, 2023Kashyap Tele-Medicines Limited announced that they will report Q4, 2023 results on May 29, 2023Board Change • Mar 13Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. CFO & Non-lndependent Director Raghav Agrawal was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 14Third quarter 2023 earnings released: EPS: ₹0 (vs ₹0.002 in 3Q 2022)Third quarter 2023 results: EPS: ₹0 (down from ₹0.002 in 3Q 2022). Revenue: ₹542.0k (down 6.6% from 3Q 2022). Net income: ₹6.0k (down 94% from 3Q 2022). Profit margin: 1.1% (down from 17% in 3Q 2022).공시 • Feb 03Kashyap Tele-Medicines Limited to Report Q3, 2023 Results on Feb 10, 2023Kashyap Tele-Medicines Limited announced that they will report Q3, 2023 results on Feb 10, 2023Board Change • Nov 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. CFO & Non-lndependent Director Raghav Agrawal was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 11Second quarter 2023 earnings released: EPS: ₹0 (vs ₹0.001 in 2Q 2022)Second quarter 2023 results: EPS: ₹0 (down from ₹0.001 in 2Q 2022). Revenue: ₹510.0k (up 7.4% from 2Q 2022). Net income: ₹13.0k (down 71% from 2Q 2022). Profit margin: 2.5% (down from 9.3% in 2Q 2022).공시 • Nov 03Kashyap Tele-Medicines Limited to Report Q2, 2023 Results on Nov 09, 2022Kashyap Tele-Medicines Limited announced that they will report Q2, 2023 results on Nov 09, 2022Board Change • Aug 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. CFO & Non-lndependent Director Raghav Agrawal was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 531960 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 531960 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장June Industries 배당 수익률 vs 시장531960의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (531960)n/a시장 하위 25% (IN)0.3%시장 상위 25% (IN)1.5%업계 평균 (IT)4.3%분석가 예측 (531960) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 531960 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 531960 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 531960 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: 531960 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YIN 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/13 23:34종가2026/06/08 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스June Industries Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • May 22Full year 2026 earnings released: ₹0.097 loss per share (vs ₹0 in FY 2025)Full year 2026 results: ₹0.097 loss per share (further deteriorated from ₹0 in FY 2025). Revenue: ₹2.16m (up 12% from FY 2025). Net loss: ₹4.61m (loss widened ₹4.60m from FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 174 percentage points per year, which is a significant difference in performance.
공시 • Apr 24June Industries Limited to Report Q4, 2026 Results on May 15, 2026June Industries Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 15, 2026
Reported Earnings • Feb 11Third quarter 2026 earnings released: ₹0.02 loss per share (vs ₹0 in 3Q 2025)Third quarter 2026 results: ₹0.02 loss per share (further deteriorated from ₹0 in 3Q 2025). Net loss: ₹942.0k (loss widened ₹920.0k from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 143% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth.
공시 • Jan 21June Industries Limited to Report Q3, 2026 Results on Feb 10, 2026June Industries Limited announced that they will report Q3, 2026 results on Feb 10, 2026
New Risk • Dec 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (₹780k revenue, or US$8.6k). Market cap is less than US$10m (₹400.9m market cap, or US$4.44m). Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change).
Buy Or Sell Opportunity • Nov 20Now 23% undervaluedOver the last 90 days, the stock has risen 4.8% to ₹10.19. The fair value is estimated to be ₹13.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 13% over the last 3 years. Earnings per share has grown by 133%.
Reported Earnings • Nov 18First half 2026 earnings released: ₹0.018 loss per share (vs ₹0.002 profit in 1H 2025)First half 2026 results: ₹0.018 loss per share (down from ₹0.002 profit in 1H 2025). Net loss: ₹869.0k (down ₹947.0k from profit in 1H 2025). Over the last 3 years on average, earnings per share has increased by 133% per year but the company’s share price has only increased by 70% per year, which means it is significantly lagging earnings growth.
공시 • Nov 03Kashyap Tele-Medicines Limited to Report First Half, 2026 Results on Nov 12, 2025Kashyap Tele-Medicines Limited announced that they will report first half, 2026 results on Nov 12, 2025
공시 • Sep 26+ 1 more updateKashyap Tele-Medicines Limited Appoints Kalpesh Bipin Sheth as Managing Director, Effective May 23, 2025Kashyap Tele-Medicines Limited at its AGM held on September 24, 2025 announced the appointment of Mr. Kalpesh Bipin Sheth (DIN: 00405151) as Managing Director of the Company, effective 23rd May, 2025 for the period of five consecutive years.
공시 • Aug 25Kashyap Tele-Medicines Limited, Annual General Meeting, Sep 24, 2025Kashyap Tele-Medicines Limited, Annual General Meeting, Sep 24, 2025, at 11:30 Indian Standard Time.
Reported Earnings • Aug 15First quarter 2026 earnings released: ₹0.006 loss per share (vs ₹0.001 profit in 1Q 2025)First quarter 2026 results: ₹0.006 loss per share (down from ₹0.001 profit in 1Q 2025). Net loss: ₹298.0k (down ₹332.0k from profit in 1Q 2025).
공시 • Aug 09Kashyap Tele-Medicines Limited to Report Q1, 2026 Results on Aug 14, 2025Kashyap Tele-Medicines Limited announced that they will report Q1, 2026 results on Aug 14, 2025
Board Change • Aug 01High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Non-Executive & Independent Director Hiren Mehta was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
New Risk • May 24New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₹860k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹860k free cash flow). Revenue is less than US$1m (₹1.9m revenue, or US$23k). Market cap is less than US$10m (₹432.8m market cap, or US$5.08m).
공시 • May 15Kashyap Tele-Medicines Limited to Report Q4, 2025 Results on May 23, 2025Kashyap Tele-Medicines Limited announced that they will report Q4, 2025 results on May 23, 2025
공시 • Apr 07Kashyap Tele-Medicines Limited Announces Resignation of Ms. Jyoti Sahu as Whole Time Company Secretary, Compliance Officer, Effective April 6, 2025Kashyap Tele-Medicines Limited announced resignation of Ms. Jyoti Sahu (ICSI A72072) from the position of Whole Time Company Secretary, Compliance Officer and Key Managerial Personnel and she shall not be associated with the Company with effect from 6th April, 2025 to explore further professional growth opportunities. Further there are no other material reasons for resignation other than the one mentioned in her resignation letter dated 5th April, 2025.
Reported Earnings • Feb 13Third quarter 2025 earnings releasedThird quarter 2025 results: EPS: ₹0. Revenue: ₹390.0k (down 14% from 3Q 2024). Net loss: ₹22.0k (down 375% from profit in 3Q 2024).
공시 • Feb 05Kashyap Tele-Medicines Limited to Report Q3, 2025 Results on Feb 12, 2025Kashyap Tele-Medicines Limited announced that they will report Q3, 2025 results on Feb 12, 2025
Reported Earnings • Nov 14Second quarter 2025 earnings releasedSecond quarter 2025 results: EPS: ₹0.001. Revenue: ₹550.0k (down 9.8% from 2Q 2024). Net income: ₹44.0k (up ₹42.0k from 2Q 2024). Profit margin: 8.0% (up from 0.3% in 2Q 2024). The increase in margin was driven by lower expenses.
New Risk • Nov 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.4% average weekly change). Earnings have declined by 29% per year over the past 5 years. Revenue is less than US$1m (₹2.0m revenue, or US$24k). Market cap is less than US$10m (₹110.2m market cap, or US$1.31m).
공시 • Nov 06Kashyap Tele-Medicines Limited to Report Q2, 2025 Results on Nov 11, 2024Kashyap Tele-Medicines Limited announced that they will report Q2, 2025 results on Nov 11, 2024
공시 • Aug 28Kashyap Tele-Medicines Limited Announces Cessation of Surabhi Agrawal from the Post of Non-Executive Independent DirectorKashyap Tele-Medicines Limited announced that the Board of Directors in its meeting held on 28 August, 2024, has inter-alia considered and taken note of the cessation of Mrs. Surabhi Agrawal from the post of Non-Executive Independent Director of the Company effective from 22 August, 2024 upon completion of second term of five consecutive years on 21 August, 2024.
공시 • Jul 30Kashyap Tele-Medicines Limited to Report Q1, 2025 Results on Aug 05, 2024Kashyap Tele-Medicines Limited announced that they will report Q1, 2025 results on Aug 05, 2024
Reported Earnings • Jul 26Full year 2024 earnings released: ₹0.006 loss per share (vs ₹0.001 profit in FY 2023)Full year 2024 results: ₹0.006 loss per share (down from ₹0.001 profit in FY 2023). Revenue: ₹1.92m (down 2.3% from FY 2023). Net loss: ₹300.0k (down ₹331.0k from profit in FY 2023).
공시 • Jul 22Kashyap Tele-Medicines Limited, Annual General Meeting, Aug 12, 2024Kashyap Tele-Medicines Limited, Annual General Meeting, Aug 12, 2024, at 15:00 Indian Standard Time.
공시 • Jul 18Kashyap Tele-Medicines Limited Announces Change in Category of Directorship of Amrita Khetan from Non-Executive Non-Independent Director to Non-Executive Independent DirectorKashyap Tele-Medicines Limited at its board meeting held on July 18, 2024 approved change in category of directorship of Mrs. Amrita Khetan (DIN: 02781781) from existing category of "Non-Executive Non-Independent Director" to "Non-Executive Independent Director" of the Company for the first term of 5 consecutive years w.e.f. 19th July, 2024 to 18th July, 2029. Mrs. Amrita Khetan has completed Master of Arts in Sociology from Techno Global University and Bachelor of Arts from Kanpur Vishwavidyalaya. She has approx. 12 years of rich experience in mentorship in Programme Management. She is working as a Team Lead & Pedagogical mentor in Redbricks Education Foundation and also experienced and expertised in strategic thinking and Business management.
New Risk • May 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 49% per year over the past 5 years. Revenue is less than US$1m (₹1.9m revenue, or US$23k). Market cap is less than US$10m (₹112.1m market cap, or US$1.34m). Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change).
공시 • May 12Kashyap Tele-Medicines Limited to Report Q4, 2024 Results on May 17, 2024Kashyap Tele-Medicines Limited announced that they will report Q4, 2024 results on May 17, 2024
공시 • Feb 28Kashyap Tele-Medicines Limited Appoints Jyoti Sahu as Company Secretary and Compliance OfficerKashyap Tele-Medicines Limited at its board meeting held on February 27, 2024, has appointed Ms. Jyoti Sahu (ACS-72072), Member of the Institute of Companies Secretaries of India as Company Secretary and Compliance Officer of the Company with effect from February 27, 2024.
New Risk • Feb 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.7% average weekly change). Earnings have declined by 49% per year over the past 5 years. Revenue is less than US$1m (₹1.9m revenue, or US$23k). Market cap is less than US$10m (₹119.3m market cap, or US$1.44m).
Reported Earnings • Feb 11Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: ₹455.0k (down 16% from 3Q 2023). Net income: ₹8.0k (up 33% from 3Q 2023). Profit margin: 1.8% (up from 1.1% in 3Q 2023). The increase in margin was driven by lower expenses.
공시 • Feb 01Kashyap Tele-Medicines Limited to Report Q3, 2024 Results on Feb 09, 2024Kashyap Tele-Medicines Limited announced that they will report Q3, 2024 results on Feb 09, 2024
공시 • Dec 28Kashyap Tele-Medicines Limited Announces Resignation of Mr. Paritosh Trivedi as Company Secretary and Compliance OfficerKashyap Tele-Medicines Limited informed that the Board of Directors at their meeting held on 27 December, 2023, considered and approved, resignation of Mr. Paritosh Trivedi, Company Secretary & Compliance Officer of the Company. Accordingly, he shall be relieved from his current responsibilities with effect from closing hours of 27th December, 2023. Reason for change: Resignation due to some personal an unavoidable reasons.
공시 • Oct 26Kashyap Tele-Medicines Limited to Report Q2, 2024 Results on Nov 06, 2023Kashyap Tele-Medicines Limited announced that they will report Q2, 2024 results on Nov 06, 2023
New Risk • Aug 04New major risk - Revenue and earnings growthEarnings have declined by 70% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 70% per year over the past 5 years. Revenue is less than US$1m (₹1.9m revenue, or US$23k). Market cap is less than US$10m (₹92.6m market cap, or US$1.12m). Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change).
공시 • Jul 30Kashyap Tele-Medicines Limited to Report Q1, 2024 Results on Aug 03, 2023Kashyap Tele-Medicines Limited announced that they will report Q1, 2024 results on Aug 03, 2023
Reported Earnings • Jul 15Full year 2023 earnings released: EPS: ₹0.001 (vs ₹0.36 loss in FY 2022)Full year 2023 results: EPS: ₹0.001 (up from ₹0.36 loss in FY 2022). Revenue: ₹1.97m (flat on FY 2022). Net income: ₹31.0k (up ₹17.3m from FY 2022). Profit margin: 1.6% (up from net loss in FY 2022).
공시 • Jul 13Kashyap Tele-Medicines Limited, Annual General Meeting, Aug 03, 2023Kashyap Tele-Medicines Limited, Annual General Meeting, Aug 03, 2023, at 12:00 Indian Standard Time. Agenda: To consider and adopt the Audited Financial Statements of the Company for the Financial Year ended March 31, 2023 together with the Report of the Board of Directors and Report of the Statutory Auditors thereon; to appoint a Director in place of Ms. Amrita Khetan who retires by rotation and being eligible, offers herself for re-appointment; to consider and approve appointment of M/s. Ravi Karia & Associates, Chartered Accountants, Ahmedabad, as Statutory Auditors of the Company and to fix their remuneration; and to consider other matters if any.
New Risk • Jun 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.0% average weekly change). Revenue is less than US$1m (₹2.0m revenue, or US$24k). Market cap is less than US$10m (₹94.5m market cap, or US$1.15m).
Reported Earnings • Jun 03Full year 2023 earnings released: EPS: ₹0.001 (vs ₹0.36 loss in FY 2022)Full year 2023 results: EPS: ₹0.001 (up from ₹0.36 loss in FY 2022). Revenue: ₹1.97m (flat on FY 2022). Net income: ₹31.0k (up ₹17.3m from FY 2022). Profit margin: 1.6% (up from net loss in FY 2022).
공시 • May 23Kashyap Tele-Medicines Limited to Report Q4, 2023 Results on May 29, 2023Kashyap Tele-Medicines Limited announced that they will report Q4, 2023 results on May 29, 2023
Board Change • Mar 13Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. CFO & Non-lndependent Director Raghav Agrawal was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 14Third quarter 2023 earnings released: EPS: ₹0 (vs ₹0.002 in 3Q 2022)Third quarter 2023 results: EPS: ₹0 (down from ₹0.002 in 3Q 2022). Revenue: ₹542.0k (down 6.6% from 3Q 2022). Net income: ₹6.0k (down 94% from 3Q 2022). Profit margin: 1.1% (down from 17% in 3Q 2022).
공시 • Feb 03Kashyap Tele-Medicines Limited to Report Q3, 2023 Results on Feb 10, 2023Kashyap Tele-Medicines Limited announced that they will report Q3, 2023 results on Feb 10, 2023
Board Change • Nov 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. CFO & Non-lndependent Director Raghav Agrawal was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 11Second quarter 2023 earnings released: EPS: ₹0 (vs ₹0.001 in 2Q 2022)Second quarter 2023 results: EPS: ₹0 (down from ₹0.001 in 2Q 2022). Revenue: ₹510.0k (up 7.4% from 2Q 2022). Net income: ₹13.0k (down 71% from 2Q 2022). Profit margin: 2.5% (down from 9.3% in 2Q 2022).
공시 • Nov 03Kashyap Tele-Medicines Limited to Report Q2, 2023 Results on Nov 09, 2022Kashyap Tele-Medicines Limited announced that they will report Q2, 2023 results on Nov 09, 2022
Board Change • Aug 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. CFO & Non-lndependent Director Raghav Agrawal was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.